Embryonic ventral mesencephalic grafts to the substantia nigra of MPTP‐treated monkeys: Feasibility relevant to multiple‐target grafting as a therapy for Parkinson's disease
Collier TJ, Sortwell CE, Elsworth JD, Taylor JR, Roth RH, Sladek JR, Redmond DE. Embryonic ventral mesencephalic grafts to the substantia nigra of MPTP‐treated monkeys: Feasibility relevant to multiple‐target grafting as a therapy for Parkinson's disease. The Journal Of Comparative Neurology 2001, 442: 320-330. PMID: 11793337, DOI: 10.1002/cne.10108.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAxonsBrain Tissue TransplantationCell DifferentiationChlorocebus aethiopsDopamineGraft SurvivalHomovanillic AcidImmunohistochemistryMaleNeostriatumNerve RegenerationNeuritesNeuronsParkinsonian DisordersRecovery of FunctionStem Cell TransplantationStem CellsSubstantia NigraTreatment OutcomeTyrosine 3-MonooxygenaseConceptsSubstantia nigraParkinson's diseaseDA neuronsVentral mesencephalonTyrosine hydroxylaseTH-positive fiber densityEmbryonic DA neuronsEmbryonic dopamine neuronsRostral substantia nigraStriatal DA depletionVentral mesencephalic graftsBasal ganglia circuitryBasal ganglia structuresSuboptimal therapeutic outcomesAfrican green monkeysDA modulationGrafted neuronsVM graftsMesencephalic graftsParkinsonian monkeysSN neuronsDA depletionReplacement therapyDA replacementDA levels